What Oftan Catachrom Treats: Main Uses and Benefits

Oftan Catachrom is commonly used in the conservative management of cataract, applied across the therapeutic domain of lens opacification. This approach is relevant for conditions presenting with symptoms that interfere with daily functioning, such as reduced visual acuity and generalized vision clouding in early to moderate stages. The medication is applied across various forms of lens clouding, including common senile cataract and those resulting from trauma. The properties of the preparation's metabolic components are relevant to the medication’s supportive use in conditions driven by metabolic changes.

This supportive action may assist with managing symptom patterns linked to clouding and may assist patients, especially older adults, with functional stability. The medication is often utilized in long-term conservative therapy when the condition is non-advanced or in situations where the patient is seeking to postpone surgical intervention. As a supportive measure, it is intended to help patients cope more steadily with symptom fluctuations, providing therapeutic relief.

“This medicine is relevant when the primary goal is to support the chronic, non-advanced stages of visual deterioration caused by lens changes.”

Quick Fact: Relevant for Vision Clouding and Reduced Acuity

This information details the populations officially eligible or strictly prohibited from using Oftan Catachrom eye drops, based on authoritative government regulatory documentation.

Who Cannot Use This Medicine

The medicine is contraindicated (must not be used) if you have a known hypersensitivity or allergy to the active substance (sodium cromoglicate) or to any of the other ingredients in the eye drop formulation. Patients with such a history are formally excluded from treatment.

Eligibility by Age and Physiological State

Population Group	Official Eligibility Status
Adults (18+ years)	Use is allowed, as the medicine's documented scope is for adults.
Children	Not suitable for use in children under 18 years of age.
Pregnancy	Use should be with caution, particularly during the first trimester, and only when there is a clear clinical need.
Lactation / Nursing	Use requires caution. It is considered unlikely that the substance is excreted in breast milk, but caution is advised due to potential systemic absorption.

Official labeling defines who cannot use the medicine primarily through the absolute contraindication of hypersensitivity, which prohibits use regardless of age or other factors. Furthermore, eligibility is restricted by age, as the use in those under 18 years is not documented as suitable. Pregnancy and lactation also impose constraints, requiring the drug’s use to be determined by caution and clinical necessity.

Interactions with other medicines and products

The interaction profile for Oftan Catachrom, a multi-component ophthalmic solution, is primarily defined by procedural requirements for co-administration with other local eye treatments rather than systemic drug-drug interactions.

Interaction Scope and Regulatory Basis

Due to the negligible systemic absorption of its active components (Cytochrome C, Nicotinamide, and Aervae Lanatae Herba) from the topical ophthalmic route, official regulatory labeling typically does not document clinically significant systemic pharmacokinetic interactions, such as those related to CYP enzymes or drug transporters.

Consequently, no specific systemic medicinal products or substance categories (including food, alcohol, or herbal products) are formally listed as contraindicated or noted for causing changes in drug exposure (e.g., AUC or Cmax) in official prescribing information for this topical agent.

---

Official Administration Constraints for Concomitant Ocular Use

The regulatory documentation establishes mandatory rules for co-administering this product with other topical medicines intended for the eye. These rules constitute the essential interaction constraints:

• Timing Separation: Co-administration with any other eye drops or ophthalmic solutions requires a minimum separation period of at least five minutes between successive applications to prevent the washout of the prior dose.
• Sequence Rule: When combining Oftan Catachrom with an ophthalmic ointment, the ointment formulation must be administered last in the sequence to ensure that the solution's absorption is not hindered.

These official statements define the product's interaction structure based on local administration requirements, which is a standard regulatory precaution for multi-dose topical ocular therapy.

Oftan Catachrom is a fixed-combination ophthalmic solution containing cytochrome C, adenosine, and nicotinamide, designed to modulate key metabolic processes in the ocular lens and anterior segment.

The pharmacodynamic mechanism involves the synergistic action of its components.

Cytochrome C acts as an antioxidant by accepting and donating electrons, primarily targeting reactive oxygen species (ROS) in the lens epithelial and fiber cells. This interaction modulates the intracellular redox potential, stabilizing cellular membranes and preventing the oxidation of structural lens proteins. As a component of the mitochondrial electron transport chain, it functions as an electron carrier between complex III and complex IV, contributing to ATP synthesis and maintaining cellular energy homeostasis.

Adenosine is an agonist at purinergic receptors, particularly the A1 and A2 receptors expressed on ocular tissues. Its binding initiates signal transduction cascades, leading to the modulation of local ocular circulation and metabolic support by influencing the release of vasodilatory mediators. It also participates directly in ATP metabolism as a precursor.

Nicotinamide (a form of Vitamin B3) acts as a metabolic precursor for the essential coenzymes nicotinamide adenine dinucleotide (NAD+) and nicotinamide adenine dinucleotide phosphate (NADP+). By increasing the cellular reservoir of these coenzymes, nicotinamide supports numerous redox reactions and cellular repair processes in the lens. This action is critical for the function of multiple enzymes necessary for lens clarity and viability. The systemic physiological consequence is the stabilization of the lens's homeostatic and energetic environment.

How Oftan Catachrom is Used: Official Administration Guidelines

Administration Scope

The administration of Oftan Catachrom is structured around its identity as a multi-component ophthalmic agent containing active components such as Cytochrome C and the metabolic cofactor Nicotinamide. The designated Route of administration is strictly topical ophthalmic instillation; the sterile solution is not intended for oral intake or injection. As a sterile aqueous drops formulation, the administration procedure requires aseptic handling to maintain the integrity of the product, a fundamental principle for all topical ocular medicines.

Instruction Classifications (High-level)	Detail
Administration Method Type	Topical instillation only.
Frequency Pattern	Divided Use Pattern (Administration is typically required multiple times per day).
Use-Context Constraints	Intended for long-term conservative therapy; primarily used in Adults and Older Adults

Resulting Procedural Structure

Use is defined by the necessary procedural steps for a sterile ocular solution. The drops must be applied by topical instillation directly into the affected eye(s) only. This administration method ensures local delivery, consistent with the formulation. While specific numeric dosing schedules are based on individual national regulatory documents and are not globally standardized under a single label, the procedural structure mandates a divided schedule to facilitate sustained contact with the ocular surface over the course of the day. The official usage protocol is thus defined by the required method of instillation and the necessity of repeated daily application over an extended period.

Research Evidence / Overview of Studies for Oftan Catachrom

This overview summarizes the type of research that has been conducted on Oftan Catachrom and its active components, reflecting the findings reported in official and scientific literature. The purpose is to describe what research exists, what it has examined, and where information remains insufficient, without providing advice or recommendations.

---

1. Research Evidence for the Conservative Management of Cataract

Oftan Catachrom was studied in research exploring the non-surgical management of age-related lens opacification (cataract) in its early to moderate stages. The available evidence includes smaller-scale clinical trials and observational studies evaluating daily-life functioning and the progression of the condition. Researchers included adults and older adults with different forms of lens clouding, seeking to understand the application of the preparation over time.

Research describes findings that indicate patterns related to changes in the rate of clouding across the intermediate follow-up periods examined. However, the evidence remains limited and heterogeneous, as the primary support comes from research that is not consistently based on large-scale Randomized Controlled Trials (RCTs). Therefore, certainty remains low when comparing these findings to research standards for newer medications.

---

2. Research on Ocular Metabolic Support

Research describes the preparation as a tissue metabolism regulator. Research explored the role of its components in cellular metabolic balance. Studies here primarily consist of basic science and molecular studies on the individual active components, particularly Nicotinamide and Cytochrome C, rather than the final multi-component eye drop. These laboratory studies research examined outcomes such as biomarkers for mitochondrial function and oxidative stress in ocular tissues.

Findings from basic science contribute to the broader evidence landscape by describing the individual components and their known functions. Research on the combined action and delivery of all three components in the finished ophthalmic solution has limited information regarding long-term outcomes and clinical relevance.

Key Studies & References Nicotinamide and Mitochondrial Function in Ocular Health: A Review (PMC Article)

Common questions about Oftan Catachrom (FAQ)

Q: Is Oftan Catachrom safe to use if I wear contact lenses?

A: Official product information notes that Oftan Catachrom contains benzalkonium chloride as a preservative. This substance can be absorbed by soft contact lenses and potentially cause discoloration. If soft contact lenses are worn, official guidelines require them to be removed before applying the drops and can be reinserted after 15 minutes.

Q: What is the difference between Oftan Catachrom and regular lubricating eye drops?

A: Oftan Catachrom is classified as an anticataract agent and a tissue metabolism regulator according to regulatory documentation. It contains three active components designed to support specific metabolic processes within the eye's lens. This mechanism differs from that of regular eye drops, which are typically used for simple surface relief or lubrication.

Q: Can I use other eye drops at the same time as Oftan Catachrom? (Re-phrased as sequence concern)

A: If another eye drop or ophthalmic solution is used concurrently, official guidelines require a minimum separation period of at least five minutes between successive applications to prevent dose washout. If an ophthalmic ointment is also used, the ointment must be applied last in the sequence.

Q: Does Oftan Catachrom contain preservatives, and is that a concern?

A: Yes, Oftan Catachrom contains benzalkonium chloride as a preservative. Official information states that this preservative may cause eye irritation, particularly for individuals with pre-existing conditions like dry eye syndrome or certain corneal issues. If irritation becomes severe or persistent, the information should be reported to a healthcare professional.

Q: Is Oftan Catachrom only for a specific stage of cataract development?

A: Research supporting the use of Oftan Catachrom primarily involves studies focusing on the non-surgical management of age-related cataract in its early to moderate stages. The medicine is administered as long-term conservative therapy.

Q: Are the ingredients in Oftan Catachrom safe for sensitive eyes?

A: The official product information notes that the preservative benzalkonium chloride may cause eye irritation. This effect is noted to be particularly relevant for individuals with pre-existing conditions such as dry eye syndrome or certain corneal issues. If irritation becomes severe or persistent, the information should be reported to a healthcare professional.

Q: What clinical trials support the use of Oftan Catachrom?

A: Official research evidence describes the availability of smaller-scale clinical trials and observational studies. These studies have mainly focused on evaluating daily-life functioning and the progression of age-related lens opacification to support its use in conservative management.

Q: Is Oftan Catachrom available over-the-counter, or is it prescription only?

A: The prescription status of Oftan Catachrom varies by country due to different regulatory decisions. Depending on the location, it may be available as either an over-the-counter (OTC) product or it may require a prescription from a licensed professional.

Q: How does Oftan Catachrom specifically target the proteins involved in cataracts?

A: The active components target key metabolic processes that may contribute to lens clouding. Specifically, Cytochrome C acts to prevent the oxidation of structural lens proteins by neutralizing reactive oxygen species (ROS). Additionally, Nicotinamide supports numerous redox reactions and cellular repair processes that are vital for maintaining lens clarity.

Q: Is it okay to drive after putting in Oftan Catachrom drops?

A: Official safety information notes that temporary blurred vision or cloudy vision may occur right after using the eye drops. If you experience visual disturbances such as blurred vision, regulatory warnings advise against driving or operating machinery until vision returns to normal.

Q: What is the typical duration of treatment with Oftan Catachrom?

A: According to the official administration scope, Oftan Catachrom is intended for long-term conservative therapy. The duration of use is typically extended and is determined by a healthcare professional based on the specific treatment plan.

Q: Why is it important to use Oftan Catachrom consistently?

A: The usage protocol is designed for a divided daily schedule over an extended period because the medicine is intended for long-term conservative therapy. This frequent application is required to facilitate sustained contact with the ocular surface and provide continuous support to the metabolic health of the eye's structures.

Q: What is the rationale behind the combination of ingredients in Oftan Catachrom?

A: The combination is specifically designed to provide a synergistic action by integrating multiple functions. The components combine antioxidant activity with key metabolic support to stabilize the lens's homeostatic and energetic environment, supporting the eye’s natural defenses and energy supply.

Q: How should I store the drops while traveling?

A: Official storage instructions state that the product must be stored at a temperature between 2 C and 8 C (refrigerated). You must also ensure the drops are protected from light and stored in a dry place to maintain the product's quality and stability.

Q: Is it common to have watery eyes after using Oftan Catachrom?

A: The most commonly reported localized reactions include temporary burning, stinging, or itching in the eye. Watery eyes (lacrimation) is not listed as a common side effect in the provided official safety summaries.

Q: Are there any known allergic reactions to Oftan Catachrom?

A: Yes, the medicine is formally contraindicated if a known hypersensitivity or allergy to any of its components exists. Additionally, rare cases of severe irritation or allergic conjunctivitis are listed among the possible uncommon or other effects.

The storage and disposal of Oftan Catachrom must strictly follow the conditions detailed in the official regulatory documentation to preserve the product's quality and integrity.

Storage Conditions and Stability

Storage Temperature Requirement:	Store at a temperature between 2 C and 8 C (refrigerated).
Light and Moisture Protection:	The product must be protected from light and stored in a dry place.
Stability After Opening:	Do not use beyond 28 days (4 weeks) after first opening the bottle.
Child Protection:	Keep out of the sight and reach of children (a mandatory safety instruction).

Handling and Disposal

• Handling: The dropper tip must not be allowed to touch the eye or any other surface to prevent contamination of the solution.
• Disposal: Any unused product or waste material should be disposed of in accordance with local requirements. The medicine must not be discarded in household waste or wastewater unless specifically instructed to do so by a local authority or pharmacist.